Role of imaging-based biomarkers in NAFLD: Recent advances in clinical application and future research directions

Journal of Hepatology

Volumn 68, Issue 2, 2018, Pages 296-304

  Loomba, Rohit ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Biomarker; MRE; VCTE

Indexed keywords

ACOUSTIC RESONANCE FORCED IMPULSE IMAGING; CLINICAL OUTCOME; COMPUTER ASSISTED TOMOGRAPHY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC IMAGING; ECHOGRAPHY; ELASTOGRAPHY; HUMAN; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING; NONALCOHOLIC FATTY LIVER; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; REVIEW; SHEAR WAVE ELASTOGRAPHY; VIBRATION CONTROLLED TRANSIENT ELASTOGRAPHY; COMPLICATION; DISEASE EXACERBATION; LIVER; PROCEDURES;

DISEASE PROGRESSION; ELASTICITY IMAGING TECHNIQUES; HUMANS; LIVER; LIVER CIRRHOSIS; NON-ALCOHOLIC FATTY LIVER DISEASE;

EID: 85037745655     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2017.11.028     Document Type: Review

References (61)

1. Chalasani, N., Younossi, Z., Lavine, J.E., et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the study of liver diseases. Hepatology, 2017.
2. Singh, S., Allen, A.M., Wang, Z., et al. Fibrosis progression in nonalcoholic fatty liver vs. nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies.Clin Gastroenterol Hepatol., 13, 2015, 643–654 e1–9; quiz e39–40.
3. Dulai, P.S., Singh, S., Patel, J., et al. Increased risk of mortality by fibrosis stage in non-alcoholic fatty liver disease: systematic review and meta-analysis. Hepatology, 2017.
4. Angulo, P., Kleiner, D.E., Dam-Larsen, S., et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 149 (2015), 389–397 e10.
5. Ekstedt, M., Hagstrom, H., Nasr, P., et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 61 (2015), 1547–1554.
6. Angulo, P., Nonalcoholic fatty liver disease. N Engl J Med 346 (2002), 1221–1231.
7. Rockey, D.C., Caldwell, S.H., Goodman, Z.D., et al. Liver biopsy. Hepatology 49 (2009), 1017–1044.
8. Castera, L., Vilgrain, V., Angulo, P., Noninvasive evaluation of NAFLD. Nat Rev Gastroenterol Hepatol 10 (2013), 666–675.
9. Chalasani, N., Younossi, Z., Lavine, J.E., et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the study of liver diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 55 (2012), 2005–2023.
10. European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, EASL clinical practice guidelines: vascular diseases of the liver. J Hepatol 64 (2016), 179–202.
11. Dulai, P.S., Sirlin, C.B., Loomba, R., MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: clinical trials to clinical practice. J Hepatol 65 (2016), 1006–1016.
12. Reeder, S.B., Cruite, I., Hamilton, G., et al. Quantitative assessment of liver fat with magnetic resonance imaging and spectroscopy. J Magn Reson Imaging 34 (2011), 729–749.
13. Wong, V.W., Wong, G.L., Yeung, D.K., et al. Incidence of non-alcoholic fatty liver disease in Hong Kong: a population study with paired proton-magnetic resonance spectroscopy. J Hepatol 62 (2015), 182–189.
14. Tang, A., Tan, J., Sun, M., et al. Nonalcoholic fatty liver disease: MR imaging of liver proton density fat fraction to assess hepatic steatosis. Radiology, 2013.
15. Schwenzer, N.F., Springer, F., Schraml, C., et al. Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. J Hepatol 51 (2009), 433–445.
16. Szczepaniak, L.S., Nurenberg, P., Leonard, D., et al. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab 288 (2005), E462–E468.
17. Dulai, P.S., Sirlin, C.B., Loomba, R., MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: clinical trials to clinical practice. J Hepatol 65 (2016), 1006–1016.
18. Loomba, R., Sirlin, C.B., Ang, B., et al. Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial). Hepatology 61 (2015), 1239–1250.
19. Le, T.A., Chen, J., Changchien, C., et al. Effect of colesevelam on liver fat quantified by magnetic resonance in nonalcoholic steatohepatitis: a randomized controlled trial. Hepatology 56 (2012), 922–932.
20. Cui, J., Philo, L., Nguyen, P., et al. Sitagliptin vs. placebo for non-alcoholic fatty liver disease: a randomized controlled trial. J Hepatol 65 (2016), 369–376.
21. Yokoo, T., Serai, S.D., Pirasteh, A., et al. Linearity, bias, and precision of hepatic proton density fat fraction measurements by using MR imaging: a meta-analysis. Radiology, 170550, 2017 [Epub ahead of print].
22. Middleton, M.S., Heba, E.R., Hooker, C.A., et al. Agreement between magnetic resonance imaging proton density fat fraction measurements and pathologist-assigned steatosis grades of liver biopsies from adults with nonalcoholic steatohepatitis. Gastroenterology, 2017.
23. Paige, J.S., Bernstein, G.S., Heba, E., et al. A pilot comparative study of quantitative ultrasound, conventional ultrasound, and MRI for predicting histology-determined steatosis grade in adult nonalcoholic fatty liver disease. AJR Am J Roentgenol 208 (2017), W168–W177.
24. Hernaez, R., Lazo, M., Bonekamp, S., et al. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology 54 (2011), 1082–1090.
25. Hamer, O.W., Aguirre, D.A., Casola, G., et al. Imaging features of perivascular fatty infiltration of the liver: initial observations. Radiology 237 (2005), 159–169.
26. Hamer, O.W., Aguirre, D.A., Casola, G., et al. Fatty liver: imaging patterns and pitfalls. Radiographics 26 (2006), 1637–1653.
27. van Werven, J.R., Marsman, H.A., Nederveen, A.J., et al. Assessment of hepatic steatosis in patients undergoing liver resection: comparison of US, CT, T1-weighted dual-echo MR imaging, and point-resolved 1H MR spectroscopy. Radiology 256 (2010), 159–168.
28. Saverymuttu, S.H., Joseph, A.E., Maxwell, J.D., Ultrasound scanning in the detection of hepatic fibrosis and steatosis. Br Med J (Clin Res Ed) 292 (1986), 13–15.
29. Hamaguchi, M., Kojima, T., Itoh, Y., et al. The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation. Am J Gastroenterol 102 (2007), 2708–2715.
30. Ballestri, S., Lonardo, A., Romagnoli, D., et al. Ultrasonographic fatty liver indicator, a novel score which rules out NASH and is correlated with metabolic parameters in NAFLD. Liver Int 32 (2012), 1242–1252.
31. Strauss, S., Gavish, E., Gottlieb, P., et al. Interobserver and intraobserver variability in the sonographic assessment of fatty liver. AJR Am J Roentgenol 189 (2007), W320–W323.
32. Fishbein, M., Castro, F., Cheruku, S., et al. Hepatic MRI for fat quantitation: its relationship to fat morphology, diagnosis, and ultrasound. J Clin Gastroenterol 39 (2005), 619–625.
33. Machado, M.V., Cortez-Pinto, H., Non-invasive diagnosis of non-alcoholic fatty liver disease. A critical appraisal. J Hepatol 58 (2013), 1007–1019.
34. Mottin, C.C., Moretto, M., Padoin, A.V., et al. The role of ultrasound in the diagnosis of hepatic steatosis in morbidly obese patients. Obes Surg 14 (2004), 635–637.
35. de Moura, Almeida A., Cotrim, H.P., Barbosa, D.B., et al. Fatty liver disease in severe obese patients: diagnostic value of abdominal ultrasound. World J Gastroenterol 14 (2008), 1415–1418.
36. Lin, S.C., Heba, E., Wolfson, T., et al. Noninvasive diagnosis of nonalcoholic fatty liver disease and quantification of liver fat using a new quantitative ultrasound technique. Clin Gastroenterol Hepatol 13 (2015), 1337–1345 e6.
37. Wong, V.W., Petta, S., Hiriart, J.B., et al. Validity criteria for the diagnosis of fatty liver by M probe-based controlled attenuation parameter. J Hepatol 67 (2017), 577–584.
38. Karlas, T., Petroff, D., Sasso, M., et al. Individual patient data meta-analysis of Controlled Attenuation Parameter (CAP) technology for assessing steatosis. J Hepatol 66 (2017), 1022–1030.
39. Petta, S., Wong, V.W., Camma, C., et al. Improved noninvasive prediction of liver fibrosis by liver stiffness measurement in patients with nonalcoholic fatty liver disease accounting for controlled attenuation parameter values. Hepatology 65 (2017), 1145–1155.
40. Chan, W.K., Nik Mustapha, N.R., Wong, G.L., et al. Controlled attenuation parameter using the FibroScan(R) XL probe for quantification of hepatic steatosis for non-alcoholic fatty liver disease in an Asian population. United European Gastroenterol J 5 (2017), 76–85.
41. Imajo, K., Kessoku, T., Honda, Y., et al. Magnetic Resonance Imaging More Accurately Classifies Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Than Transient Elastography. Gastroenterology 150 (2016), 626–637 e7.
42. Park, C.C., Nguyen, P., Hernandez, C., et al. Magnetic resonance elastography vs. transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy-proven nonalcoholic fatty liver disease. Gastroenterology 152 (2017), 598–607 e2.
43. de Ledinghen, V., Vergniol, J., Capdepont, M., et al. Controlled attenuation parameter (CAP) for the diagnosis of steatosis: a prospective study of 5323 examinations. J Hepatol 60 (2014), 1026–1031.
44. Foucher, J., Castera, L., Bernard, P.H., et al. Prevalence and factors associated with failure of liver stiffness measurement using FibroScan in a prospective study of 2114 examinations. Eur J Gastroenterol Hepatol 18 (2006), 411–412.
45. Vuppalanchi, R., Siddiqui, M.S., Van Natta, M.L., et al. Performance Characteristics of Vibration-Controlled Transient Elastography for Evaluation of Non-Alcoholic Fatty Liver Disease. Hepatology, 2017.
46. de Ledinghen, V., Wong, V.W., Vergniol, J., et al. Diagnosis of liver fibrosis and cirrhosis using liver stiffness measurement: comparison between M and XL probe of FibroScan(R). J Hepatol 56 (2012), 833–839.
47. Wong, V.W., Vergniol, J., Wong, G.L., et al. Liver stiffness measurement using XL probe in patients with nonalcoholic fatty liver disease. Am J Gastroenterol 107 (2012), 1862–1871.
48. Tapper, E.B., Challies, T., Nasser, I., et al. The performance of vibration controlled transient elastography in a US cohort of patients with nonalcoholic fatty liver disease. Am J Gastroenterol 111 (2016), 677–684.
49. Palmeri, M.L., Wang, M.H., Rouze, N.C., et al. Noninvasive evaluation of hepatic fibrosis using acoustic radiation force-based shear stiffness in patients with nonalcoholic fatty liver disease. J Hepatol 55 (2011), 666–672.
50. Liu, H., Fu, J., Hong, R., et al. Acoustic radiation force impulse elastography for the non-invasive evaluation of hepatic fibrosis in non-alcoholic fatty liver disease patients: a systematic review & meta-analysis. PLoS One, 10, 2015, e0127782.
51. Chen, J., Yin, M., Talwalkar, J.A., et al. Diagnostic performance of MR elastography and vibration-controlled transient elastography in the detection of hepatic fibrosis in patients with severe to morbid obesity. Radiology 283 (2017), 418–428.
52. Cassinotto, C., Boursier, J., de Lédinghen, V., et al. Liver stiffness in nonalcoholic fatty liver disease: a comparison of supersonic shear imaging, FibroScan, and ARFI with liver biopsy. Hepatology, 2016.
53. Cui, J., Heba, E., Hernandez, C., et al. Magnetic resonance elastography is superior to acoustic radiation force impulse for the diagnosis of fibrosis in patients with biopsy-proven nonalcoholic fatty liver disease: a prospective study. Hepatology 63 (2016), 453–461.
54. Loomba, R., Cui, J., Wolfson, T., et al. Novel 3D magnetic resonance elastography for the noninvasive diagnosis of advanced fibrosis in NAFLD: a prospective study. Am J Gastroenterol, 2016.
55. Pavlides, M., Banerjee, R., Sellwood, J., et al. Multiparametric magnetic resonance imaging predicts clinical outcomes in patients with chronic liver disease. J Hepatol 64 (2016), 308–315.
56. Pavlides, M., Banerjee, R., Tunnicliffe, E.M., et al. Multiparametric magnetic resonance imaging for the assessment of non-alcoholic fatty liver disease severity. Liver Int 37 (2017), 1065–1073.
57. Yin, M., Glaser, K.J., Manduca, A., et al. Distinguishing between hepatic inflammation and fibrosis with MR elastography. Radiology 284 (2017), 694–705.
58. Patel, J., Bettencourt, R., Cui, J., et al. Association of noninvasive quantitative decline in liver fat content on MRI with histologic response in nonalcoholic steatohepatitis. Therap Adv Gastroenterol 9 (2016), 692–701.
59. Patel, N.S., Hooker, J., Gonzalez, M., et al. Weight loss decreases magnetic resonance elastography estimated liver stiffness in nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 15 (2017), 463–464.
60. Caussy, C., Alquiraish, M.H., Nguyen, P., et al. Optimal threshold of controlled attenuation parameter with MRI-PDFF as the gold standard for the detection of hepatic steatosis. Hepatology, 2017.
61. Caussy, C., Chen, J., Alquiraish, M.H., et al. Association between obesity and discordance in fibrosis stage determination by magnetic resonance vs. transient elastography in patients with non-alcoholic liver disease. Clin Gastroenterol Hepatol, 2017.